Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2D6 , ADRB1 , ADRB2 , ADRA2C , GRK4 , and GRK5 Genotypes and Beta‐Blocker Therapy

Beta‐blockers are widely used medications for a variety of indications, including heart failure, myocardial infarction, cardiac arrhythmias, and hypertension. Genetic variability in pharmacokinetic (e.g., CYP2D6 ) and pharmacodynamic (e.g., ADRB1 , ADRB2 , ADRA2C , GRK4 , GRK5 ) genes have been stud...

Full description

Saved in:
Bibliographic Details
Published in:Clinical pharmacology and therapeutics 2024-07, Vol.116 (4), p.939-947
Main Authors: Duarte, Julio D., Thomas, Cameron D., Lee, Craig R., Huddart, Rachel, Agundez, Jose A. G., Baye, Jordan F., Gaedigk, Andrea, Klein, Teri E., Lanfear, David E., Monte, Andrew A., Nagy, Mohamed, Schwab, Matthias, Stein, C. Michael, Uppugunduri, Chakradhara Rao S., van Schaik, Ron H. N., Donnelly, Roseann S., Caudle, Kelly E., Luzum, Jasmine A.
Format: Article
Language:English
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Beta‐blockers are widely used medications for a variety of indications, including heart failure, myocardial infarction, cardiac arrhythmias, and hypertension. Genetic variability in pharmacokinetic (e.g., CYP2D6 ) and pharmacodynamic (e.g., ADRB1 , ADRB2 , ADRA2C , GRK4 , GRK5 ) genes have been studied in relation to beta‐blocker exposure and response. We searched and summarized the strength of the evidence linking beta‐blocker exposure and response with the six genes listed above. The level of evidence was high for associations between CYP2D6 genetic variation and both metoprolol exposure and heart rate response. Evidence indicates that CYP2D6 poor metabolizers experience clinically significant greater exposure and lower heart rate in response to metoprolol compared with those who are not poor metabolizers. Therefore, we provide therapeutic recommendations regarding genetically predicted CYP2D6 metabolizer status and metoprolol therapy. However, there was insufficient evidence to make therapeutic recommendations for CYP2D6 and other beta‐blockers or for any beta‐blocker and the other five genes evaluated (updates at www.cpicpgx.org ).
ISSN:0009-9236
1532-6535
1532-6535
DOI:10.1002/cpt.3351